Sp730
CURRENT SUCCESSES AND FUTURE CHALLENGES FOR 2024 AND BEYOND
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
Presenter
University of Washington
Tracks
Related Products
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AGA Getting Off the Menu and Back at the Table: Challenges for GI in Advocacy
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
INTRODUCTION
SOCIETY: AGA
PANEL DISCUSSION
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
